Enterprise Value

0.00

Cash

52.2M

Avg Qtr Burn

N/A

Short % of Float

2.66%

Insider Ownership

0.41%

Institutional Own.

20.37%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2b

Update

Phase 2b

Update

Phase 2

Update

Maveropepimut-S (DPX-Survivac) (Survivin) Details
Cancer, Solid tumor/s, Breast cancer

Phase 1b

Update

DPX-RSV Details
Respiratory syncytial virus

Failed

Discontinued

Maveropepimut-S (DPX-Survivac) (Survivin) + CPA + Keytruda Details
Ovarian cancer, Bladder cancer, Liver cancer, Cancer

Failed

Discontinued

Failed

Discontinued